目的 探讨黄葵胶囊联合贝前列素钠缓释片治疗慢性肾功能衰竭维持性血液透析的临床疗效。方法 选取2022年10月—2024年11月在恩施州中心医院就诊的慢性肾功能衰竭维持性血液透析的患者共计90例，按随机数字表法分为对照组和治疗组，每组45例。对照组早晚餐后口服贝前列素钠缓释片，1片/次。治疗组在对照组基础上口服黄葵胶囊，5粒/次，3次/d。两组患者连续治疗8周。比较两组临床疗效、日常生活能力、肾功能指标和血清炎症因子。结果 对照组患者的总有效率为68.89%，治疗组患者的总有效率为86.67%，组间比较差异显著（P＜0.05）。治疗后，两组的日常生活能力量表（ADL）评分显著升高（P＜0.05），且治疗组的ADL评分高于对照组（P＜0.05）。治疗后，两组的肾小球滤过率（GFR）明显升高，肌酐（Scr）、胱抑素C（Cys-C）、β2-微球蛋白（β2-MG）明显降低（P＜0.05）；治疗后，治疗组的GFR高于对照组，Scr、Cys-C、β2-MG低于对照组（P＜0.05）。治疗后，两组的血清肾损伤分子-1（KIM-1）、亲环素A（CyPA）、转化生长因子-β1（TGF-β1）水平降低（P＜0.05）；治疗后，治疗组的血清KIM-1、CyPA、TGF-β1水平低于对照组（P＜0.05）。结论 黄葵胶囊联合贝前列素钠缓释片可提高慢性肾功能衰竭维持性血液透析的临床疗效，通过减轻肾组织炎性损伤以保护残余肾功能，提高日常生活能力。

Objective To explore the clinical efficacy of Huangkui Capsules combined with Beraprost Sodium Sustained-release Tablets in treatment of chronic renal failure and maintenance hemodialysis. Methods 90 Patients with chronic renal failure undergoing maintenance hemodialysis in The Central Hospital of Enshi Tujia and Miao Automomous Prefectur from October 2022 to November 2024 were divided into control group and treatment group according to the random number table method, 45 cases in each group. Patients in the control group took Beraprost Sodium Sustained-release Tablets orally after breakfast and dinner, 1 tablets/time. Patients in the treatment group took Huangkui Capsules orally on the basis of the control group, 5 capsules/time, 3 times daily. Patients in two groups were treated continuously for 8 weeks. The clinical efficacy, daily living ability, renal function indicators, and serum inflammatory factors were compared between two groups. Results The total effective rate (68.89%) of treatment in the control group was lower than 86.67% in the treatment group, with significant difference between two groups (P < 0.05). After treatment, ADL scores of two groups were significantly increased (P < 0.05), and ADL scores in the treatment group were higher than those in the control group (P < 0.05). After treatment, GFR in both groups were significantly increased, but Scr, Cys-C, and β2-MG were significantly decreased (P < 0.05). After treatment, GFR in the treatment group was higher than that of the control group, while Scr, Cys-C, and β2-MG were lower than those in the control group (P < 0.05). After treatment, serum levels of KIM-1, CyPA, and TGF-β1 in both groups were decreased (P < 0.05), and serum levels of KIM-1, CyPA, and TGF-β1 in the treatment group were lower than those in the control group (P < 0.05). Conclusion Huangkui Capsules combined with Beraprost Sodium Sustained-release Tablets can improve the efficacy of chronic renal failure and maintenance hemodialysis, protect residual renal function by reducing inflammatory damage of renal tissue, and improve daily living ability.

R983

乌鲁木齐市卫生局科学技术计划项目（201618）